Clinical Trial Update: Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating erlotinib in combination with bevacizumab as second-line therapy for non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: TERMINATED